Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Open-label Single Center Study to Evaluate the Efficacy of Apremilast for the Treatment of Moderate Hidradenitis Suppurativa

NCT02695212 is registered in ClinicalTrials.gov with Florida Academic Dermatology Centers as lead sponsor.

NCT NCT02695212
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02695212 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Open-label Single Center Study to Evaluate the Efficacy of Apremilast for the Treatment of Moderate Hidradenitis Suppurativa
Lead sponsor
Florida Academic Dermatology Centers
Phase
Phase 2
Overall status
Completed
Start date
July 31, 2016
Completion date
August 31, 2017
Enrollment
20 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hidradenitis suppurativa